Opebacan(Opebacan) - _专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Neuprex、Opebacan (USAN/INN)、Recombinant bactericidal permeability increasing protein 21

+ [2]

靶点-

作用机制

血管生成抑制剂、细胞膜通透性增强剂

治疗领域

感染免疫系统疾病其他疾病

在研适应症-

非在研适应症

移植物抗宿主病脑膜炎球菌感染辐射损伤+ [2]

原研机构

XOMA Royalty Corp.

在研机构-

非在研机构

XOMA (US) LLC

XOMA Royalty Corp.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 524440693

来源: *****

关联

2

项与 Opebacan 相关的临床试验

NCT00454155 / Terminated临床1/2期

A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (rBPI21) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

The objectives of this study are as follows:
To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation
To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantation
To determine if IV administration of opebacan is associated with changes in biological markers for inflammation
To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem Cell Transplantation related complications, including aGvHD

开始日期2007-02-01

申办/合作机构

XOMA (US) LLC

NCT00462904 / Terminated临床2期IIT

Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.

The purpose of this study is to evaluate the safety of a protein called BPI that is naturally made by the body's white blood cells to fight infection.

开始日期2006-04-01

申办/合作机构

The University of Texas Southwestern Medical Center

100 项与 Opebacan 相关的临床结果

登录后查看更多信息

100 项与 Opebacan 相关的转化医学

登录后查看更多信息

100 项与 Opebacan 相关的专利（医药）

登录后查看更多信息

58

项与 Opebacan 相关的文献（医药）

2020-08-01·Molecular Therapy1区 · 医学

Antibacterial Fusion Protein BPI21/LL-37 Modification Enhances the Therapeutic Efficacy of hUC-MSCs in Sepsis

1区 · 医学

Article

作者: Jiang, Dongpo ; Li, Zhan ; Wu, Xiaofeng ; Guo, Wei ; Liang, Huaping ; Tan, Yan ; Ao, Luoquan ; Song, Yuqing ; Ao, Xiang ; He, Xiao ; Hu, Xueting ; Xing, Wei ; Yuan, Peisong ; Xu, Xiang

Sepsis, which is characterized by multiple organ dysfunctions as a result of an unbalanced host-inflammatory response to pathogens, is potentially a life-threatening condition and a major cause of death in the intensive care units (ICUs). However, effective treatment or intervention to prevent sepsis-associated lethality is still lacking. Human umbilical cord mesenchymal stem cell (hUC-MSC) transplantation has been shown to have potent immunomodulatory properties and improve tissue repair yet lacks direct antibacterial and endotoxin clearance activities. In this study, we engineered hUC-MSCs to express a broad-spectrum antibacterial fusion peptide containing BPI21 and LL-37 (named BPI21/LL-37) and confirmed that the BPI21/LL-37 modification did not affect the stemness and immunoregulatory capacities of hUC-MSCs but remarkably, enhanced its antibacterial and toxin-neutralizing activities in vitro. Furthermore, we showed that administration of BPI21/LL-37-engineered hUC-MSCs significantly reduces serum levels of tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), and IL-6, whereas increases that of IL-10 in cecal ligation and puncture (CLP)-induced sepsis mouse model. Administration of BPI21/LL-37-engineered hUC-MSCs significantly reduced systemic endotoxin (lipopolysaccharide [LPS]) levels and organ bacterial load, ameliorated damage to multiple organs, and improved survival. Taken together, our study demonstrates that BPI21/LL-37-engineered hUC-MSCs might offer a novel therapeutic strategy to prevent or treat sepsis via enhanced antimicrobial and anti-inflammatory properties to preserve organ functions better.

2017-06-07·Annals of Agricultural and Environmental Medicine4区 · 医学

Utilisation of peptides against microbial infections – a review

4区 · 医学

ArticleOA

作者: Niemcewicz, Marcin ; Gryko, Romuald ; Michalski, Aleksander ; Mirski, Tomasz ; Bartoszcze, Michał

The emergence of resistance in microorganisms on a global scale has made it necessary to search for new antimicrobial factors. Antimicrobial peptides (AMPs) seem to meet these expectations. AMPs are produced by bacteria, viruses, plants, and animals, and may be considered as a new class of drugs intended for the prophylaxis and treatment of both systemic and topical infections. The aim of this study is to review the results of studies on the use of peptides to combat infections in vivo. Antimicrobial peptides may be applied topically and systemically. Among the peptides used topically, a very important area for their application is ophthalmology. AMPs in ophthalmology may be used mainly for the protection of contact lenses from ocular pathogens. Many AMPs are in clinical trials for application in the therapy of local infections. There may be mentioned such preparations as: pexiganan (magainin analogue), MX-226 (based on indolicidin), NEUPREX (isolated from human BPI (bactericidal/permeability-increasing) protein), IB-367 (variant of porcine protegrin), P113 (based on histatin), daptomycin, polymyxins, as well as peptidomimetics. In the combat against systemic infections are used such peptides as: P113D (modified P113 peptide containing D-amino acids), colistin, peptoids, and peptides containing non-typical amino acids or non-peptide elements. AMPs are also used as antiprotozoal, antifungal, antitoxic and immunostimulatory agents. The limitations in the use of peptides in the treatment of infections, such as susceptibility to proteolysis, and resistance of microorganisms to the peptides, are also discussed. AMPs are a promising strategy in the fight against microbial infections.

2014-04-01·Nanomedicine: Nanotechnology, Biology and Medicine2区 · 医学

Antimicrobial protein rBPI21-induced surface changes on Gram-negative and Gram-positive bacteria

2区 · 医学

Article

作者: Franquelim, Henri G ; Santos, Nuno C ; Carvalho, Filomena A ; Castanho, Miguel A R B ; Silva, Patrícia M ; Domingues, Marco M

New classes of antibiotics, such as antimicrobial peptides or proteins (AMPs), are crucial to deal with threatening bacterial diseases. rBPI21 is an AMP based on the human neutrophil BPI protein, with potential clinical use against meningitis. We studied the membrane perturbations promoted by rBPI21 on Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus. Its interaction with bacteria was also studied in the presence of lipopolysaccharide (LPS), rBPI21 major ligand. Flow cytometry analysis of both bacteria shows that rBPI21 induces membrane depolarization. rBPI21 increases the negative surface charge of both bacteria toward positive values, as shown by zeta-potential measurements. This is followed by surface perturbations, culminating in cell lysis, as visualized by atomic force microscopy (AFM). Force spectroscopy measurements show that soluble LPS decreases the interaction of rBPI21 with bacteria, especially with S. aureus. This suggests that the rBPI21 LPS-binding pocket may also participate on the binding to Gram-positive bacteria.FROM THE CLINICAL EDITORIn this study, rBPI21, an antimicrobial protein based on the human neutrophil BPI protein, with potential clinical use against meningitis, is analyzed with multiple tools including zeta-potential measurements, clarifying its actions on E. coli and S. aureus. Since antimicrobial peptides are potentially important new additions to antibiotic regimens, studies like this represent important cornerstones in efficiency and mechanism of action testing of these new approaches.

100 项与 Opebacan 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05265	-	-	DB06161

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
移植物抗宿主病	临床3期	美国	XOMA (US) LLC	2007-02-01
脑膜炎球菌感染	临床3期	-	XOMA Royalty Corp.	-
辐射损伤	临床3期	-	XOMA Royalty Corp.	-
手术伤口感染	临床3期	-	XOMA Royalty Corp.	-
伤口感染	临床3期	-	XOMA Royalty Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00462904 (CTgov)	临床2期	烧伤	4	BPI	簾鹽鏇製淵廠觸觸廠構(鬱襯觸廠構鑰選艱顧艱) = 餘選鏇觸憲簾廠觸膚窪壓衊襯鬱襯鬱鹽選獵膚 (壓襯鏇窪築鬱選簾顧膚, 鏇遞淵繭糧餘遞製築糧 ~ 製選網網鏇獵鹽顧構夢) 更多	-	2019-11-20